Lundbeck’s next chapter: from psychiatry to rare neuro

While Lundbeck has yet to fully shake off its reputation as an old-school small molecule psychiatry play, the company is deep into a transformation that has taken it into other areas of neuroscience and new technology spaces.

Eighteen months into the tenure of President and CEO Charl van Zyl,  H. Lundbeck A/S (CSE:HLUN B) aims to persuade investors and partners that it’s a player — and competitor — across a broadening range of CNS disorders. The company’s evolution has come through raising the bar in psychiatry, building out its modality toolkit and seeking opportunities in rare neurology. The company’s most significant move in rare neuro came in October, when it acquired Longboard Pharmaceuticals Inc. for $2.6 billion, marking its biggest M&A deal ever and giving it a Phase III asset for rare developmental seizure disorders...